TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36113538

Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S vaccine (primary dose plus booster dose at 2 months)
Number of subjects: 31300

Group type: COMPARATOR
Intervention: Placebo injections (two injections 2 months apart)
Number of subjects: 31300

Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S vaccine (primary and booster doses)
Number of subjects: 31300

Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S vaccine (booster dose)
Number of subjects: 31300
Study: 33932790

Group type: EXPERIMENTAL
Intervention: High diet quality (measured by Australian Recommended Food Score)
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Vegetable sub-score of diet quality
Number of subjects: 392
Study: 36150646

Group type: EXPERIMENTAL
Intervention: Wide Area Transepithelial Sampling (WATS)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Forceps Biopsy (FB)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Combination of WATS and FB
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: WATS
Number of subjects: 172

Group type: COMPARATOR
Intervention: FB
Number of subjects: 172
Study: 33124717

Group type: EXPERIMENTAL
Intervention: Urban demand for wild meat consumption
Number of subjects: 4132

Group type: EXPERIMENTAL
Intervention: Duration of rural‐to‐urban migration
Number of subjects: 4132

Group type: EXPERIMENTAL
Intervention: Size of urban area
Number of subjects: 4132

Group type: EXPERIMENTAL
Intervention: Age group comparison
Number of subjects: 4132

Group type: EXPERIMENTAL
Intervention: Generational change
Number of subjects: 4132

Group type: EXPERIMENTAL
Intervention: Conservation actions
Number of subjects: 4132
Study: 34986166

Group type: EXPERIMENTAL
Intervention: GP-delivered individualised medication review
Number of subjects: 404

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 404
Study: 35994192

Group type: EXPERIMENTAL
Intervention: Interventions aimed at reducing disparities in social and behavioral outcomes
Number of subjects: 90880
Study: 32847705

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) sessions (6 sessions: 2 educational and 4 motivational)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no MI intervention)
Number of subjects: 120
Study: 34100234

Group type: EXPERIMENTAL
Intervention: ElderTree (eHealth intervention)
Number of subjects: 390

Group type: COMPARATOR
Intervention: Control (no access to ElderTree)
Number of subjects: 390
Study: 32151464

Group type: EXPERIMENTAL
Intervention: Transradial access
Number of subjects: 934

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 934

Group type: COMPARATOR
Intervention: Transfemoral access
Number of subjects: 934

Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 934
Study: 36170654

Group type: EXPERIMENTAL
Intervention: Roflumilast
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 33468129

Group type: EXPERIMENTAL
Intervention: GI boards (quality oriented and socially integrated)
Number of subjects: 109

Group type: COMPARATOR
Intervention: non-GI boards (lacking quality orientation and social integration)
Number of subjects: 109
Study: 32426471

Group type: EXPERIMENTAL
Intervention: Social-belonging intervention delivered in the first year of college (1-hour exercise)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study: 33629468

Group type: EXPERIMENTAL
Intervention: Patients with acne vulgaris
Number of subjects: 90
Study: 32186216

Group type: EXPERIMENTAL
Intervention: L-DOPA
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 36167367

Group type: EXPERIMENTAL
Intervention: Intravenous iron
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Combination of intravenous iron and tranexamic acid
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control group without treatment
Number of subjects: 126
Study: 34106652

Group type: EXPERIMENTAL
Intervention: TSLCB (experimental group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Visual estimation and traditional plastic blood‐collecting consumables (control group)
Number of subjects: 60
Study: 32609576

Group type: COMPARATOR
Intervention: Conventional frenectomy operation (C group)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Diode laser‐assisted frenectomy (L group)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Diode laser‐assisted frenectomy with conventional horizontal incision on the periosteum (L + P group)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: All groups (C, L, L + P)
Number of subjects: 48
Study: 35051233

Group type: EXPERIMENTAL
Intervention: Integrative neuromuscular training (INT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 24
Study: 33507774

Group type: EXPERIMENTAL
Intervention: ACCESS (cognitive-behavioral therapy program)
Number of subjects: 250
Study: 32408116

Group type: EXPERIMENTAL
Intervention: Sexual minority males
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Sexual minority females
Number of subjects: 535

Group type: COMPARATOR
Intervention: Heterosexual males
Number of subjects: 535

Group type: COMPARATOR
Intervention: Heterosexual females
Number of subjects: 535
Study: 35750379

Group type: EXPERIMENTAL
Intervention: Reintegration into normal life care plan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 34728723

Group type: EXPERIMENTAL
Intervention: DHA-rich algae oil supplementation
Number of subjects: 0
Study: 32562710

Group type: EXPERIMENTAL
Intervention: Inter-stimulus randomisation (IR) protocol
Number of subjects: 11

Group type: COMPARATOR
Intervention: Increasing blocks (IB) protocol
Number of subjects: 11

Group type: COMPARATOR
Intervention: Randomised blocks (RB) protocol
Number of subjects: 11
Study: 33446402

Group type: EXPERIMENTAL
Intervention: Diversion prevention strategies
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Knowledge/skill of PCPs
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Attitudes about the effectiveness of diversion prevention
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Implementation climate
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Resource constraints
Number of subjects: 76
Study: 33650799

Group type: EXPERIMENTAL
Intervention: Intensive follow-up group
Number of subjects: 196

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 196
Study: 32726556

Group type: EXPERIMENTAL
Intervention: Multiple punctures injection technique of incobotulinumtoxin A (IncoA; Xeomin)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Radial injection technique of incobotulinumtoxin A (IncoA; Xeomin)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both techniques of incobotulinumtoxin A (IncoA; Xeomin)
Number of subjects: 24
Study: 35470152

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Social Skills Training (CBSST) adapted for CHR youth
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cognitive-Behavioral Social Skills Training (CBSST)
Number of subjects: 0
Study: 34164664

Group type: EXPERIMENTAL
Intervention: COVID-19 patients with PE
Number of subjects: 368

Group type: COMPARATOR
Intervention: COVID-19 patients without PE
Number of subjects: 368

Group type: COMPARATOR
Intervention: COVID-19 patients with PE ruled out by scanner
Number of subjects: 368

Group type: COMPARATOR
Intervention: Non-COVID-19 patients with PE
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: COVID-19 population
Number of subjects: 368
Study: 32657909

Group type: EXPERIMENTAL
Intervention: r-ATG/EVR
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: BAS/EVR
Number of subjects: 274

Group type: COMPARATOR
Intervention: BAS/MPS
Number of subjects: 274
Study: 35343353

Group type: EXPERIMENTAL
Intervention: Bright light (900 lx)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard light (90 lx)
Number of subjects: 0
Study: 34259459

Group type: EXPERIMENTAL
Intervention: High-performing resident
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Average-performing resident
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Low-performing resident
Number of subjects: 43
Study: 32053478

Group type: EXPERIMENTAL
Intervention: Physical fitness tests (sit-and-reach, grip strength, sit-ups, one-leg standing, reaction time, leg extension power)
Number of subjects: 2267
Study: 33882760

Group type: EXPERIMENTAL
Intervention: Value-affirmation condition
Number of subjects: 220

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 220
Study: 32277357

Group type: EXPERIMENTAL
Intervention: Narrow gastrojejunostomy (30 mm)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Wide gastrojejunostomy (45 mm)
Number of subjects: 83
Study: 35454318

Group type: EXPERIMENTAL
Intervention: Repeated injection of 2 mL of 1% lidocaine (three injections; one injection per week)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Radial extracorporeal shock wave therapy (rESWT) (three treatment sessions; one treatment session per week; 2000 radial extracorporeal shock waves per treatment session; positive energy flux density = 0.10 mJ/mm2)
Number of subjects: 60
Study: 33184650

Group type: EXPERIMENTAL
Intervention: Lower-sodium oxybate (LXB)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study: 32997386

Group type: EXPERIMENTAL
Intervention: Antibiotics prescribed following RTI-related GP consultation
Number of subjects: 992

Group type: COMPARATOR
Intervention: Control group (children without DS)
Number of subjects: 992
Study: 34107786

Group type: EXPERIMENTAL
Intervention: Intramedullary headless cannulated screws (IHCS)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Locked miniplates
Number of subjects: 69
Study: 36490292

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT) intervention, average of 12 sessions
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT) intervention
Number of subjects: 6
Study: 34645660

Group type: EXPERIMENTAL
Intervention: Ibuprofen alone
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Ibuprofen and short intervention
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Metamizole alone
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Metamizole and short intervention
Number of subjects: 120

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Short educational intervention
Number of subjects: 120
Study: 36096282

Group type: EXPERIMENTAL
Intervention: Family‐DSMES
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard‐DSMES
Number of subjects: 0
Study: 33517541

Group type: EXPERIMENTAL
Intervention: Nimotuzumab combined with cisplatin
Number of subjects: 104

Group type: COMPARATOR
Intervention: Cisplatin
Number of subjects: 104
Study: 32616271

Group type: EXPERIMENTAL
Intervention: 0.15% functional oils
Number of subjects: 585

Group type: EXPERIMENTAL
Intervention: 66-ppm monensin
Number of subjects: 585

Group type: COMPARATOR
Intervention: Control (nonmedicated)
Number of subjects: 585

Group type: EXPERIMENTAL
Intervention: 20 ppm of virginiamycin
Number of subjects: 585

Group type: COMPARATOR
Intervention: Control (no additive)
Number of subjects: 585
Study: 35916290

Group type: EXPERIMENTAL
Intervention: Secukinumab 300mg with loading dose
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: Secukinumab 150mg with loading dose
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: Secukinumab 150mg without loading dose
Number of subjects: 389

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 389
Study: 33478593

Group type: EXPERIMENTAL
Intervention: EMOTION intervention (10-week CBT-based transdiagnostic intervention)
Number of subjects: 795

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 795
Study: 32465000

Group type: EXPERIMENTAL
Intervention: Riociguat (up to 2.5 mg tid)
Number of subjects: 340

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Riociguat and Placebo (combined analysis)
Number of subjects: 340
Study: 35430027

Group type: EXPERIMENTAL
Intervention: Focal psychodynamic therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Optimised treatment as usual
Number of subjects: 0
Study: 33246481

Group type: EXPERIMENTAL
Intervention: Zirconia frameworks with ceramic veneering
Number of subjects: 44

Group type: COMPARATOR
Intervention: Titanium frameworks with acrylic resin veneering
Number of subjects: 44
Study: 33463367

Group type: EXPERIMENTAL
Intervention: Active participation in Cantonese opera (ACO)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Passive participation in Cantonese opera (PCO)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Cantonese opera intervention (ACO and PCO combined)
Number of subjects: 95
Study: 33615843

Group type: EXPERIMENTAL
Intervention: Unblinded nitroglycerin infusion at 0.5 µg/kg/min for 20 minutes
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Single-blinded nitroglycerin infusion
Number of subjects: 33

Group type: COMPARATOR
Intervention: Single-blinded placebo infusion
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Unblinded nitroglycerin infusion
Number of subjects: 33
Study: 35687936

Group type: EXPERIMENTAL
Intervention: Brief cannabis intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 34624104

Group type: EXPERIMENTAL
Intervention: Remaining Dentin Ferrule (RDF) with mechanical fatigue (F)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Without Dentin Ferrule (WDF) with mechanical fatigue (F)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Remaining Dentin Ferrule (RDF) with control (C)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Without Dentin Ferrule (WDF) with control (C)
Number of subjects: 32
Study: 36470556

Group type: EXPERIMENTAL
Intervention: Medically tailored meals (MTM) plus lifestyle intervention
Number of subjects: 200

Group type: COMPARATOR
Intervention: Food subsidy ($40/month)
Number of subjects: 200
Study: 33933059

Group type: EXPERIMENTAL
Intervention: Vitamin K2 (360 μg MK-7 daily for 12 weeks)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 32118347

Group type: EXPERIMENTAL
Intervention: Patient-managed (nurse-assisted) titration of Gla-300
Number of subjects: 355

Group type: COMPARATOR
Intervention: Physician-managed titration of Gla-300
Number of subjects: 355
Study: 35193044

Group type: EXPERIMENTAL
Intervention: Socially-evaluated cold pressor test (seCPT, n = 29)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control condition (warm water, n = 34)
Number of subjects: 63
Study: 33236518

Group type: EXPERIMENTAL
Intervention: SARAsp‐Mix
Number of subjects: 52

Group type: COMPARATOR
Intervention: NN‐Mix‐US
Number of subjects: 52

Group type: COMPARATOR
Intervention: NN‐Mix‐EU
Number of subjects: 52

Group type: COMPARATOR
Intervention: SAR‐Asp
Number of subjects: 52
Study: 35156756

Group type: EXPERIMENTAL
Intervention: e-Learning module (30-minute duration)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Control group (test-retest approach)
Number of subjects: 177
Study: 34420049

Group type: EXPERIMENTAL
Intervention: Dispersible paediatric fixed dose combination (FDC) tablets delivering higher doses of first‐line antituberculosis drugs (rifampicin/isoniazid/pyrazinamide 75/50/150 mg, with or without 100 mg ethambutol, or rifampicin/isoniazid 75/50 mg)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Recommended weight-band based FDC doses
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Ethambutol at current WHO-recommended doses
Number of subjects: 77
Study: 35076697

Group type: EXPERIMENTAL
Intervention: Blinded continuous glucose monitoring (CGM) for a minimum of 6.5 days (average 11.9 days)
Number of subjects: 765

Group type: EXPERIMENTAL
Intervention: Use of insulin pumps and CGM
Number of subjects: 765

Group type: EXPERIMENTAL
Intervention: Routine CGM and insulin pumps
Number of subjects: 765
Study: 32900915

Group type: EXPERIMENTAL
Intervention: Emotional labor and mental health questionnaire
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: App designed to evaluate mental health status
Number of subjects: 352
Study: 35706121

Group type: EXPERIMENTAL
Intervention: Radial extracorporeal shock wave therapy
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Local corticosteroid injection
Number of subjects: 72

Group type: COMPARATOR
Intervention: Resting hand splint (Control)
Number of subjects: 72
Study: 32604224

Group type: EXPERIMENTAL
Intervention: Xinmailong injection (XMLI)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study: 32993367

Group type: EXPERIMENTAL
Intervention: Positive transition experience
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Lower role stress
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Hypothesized model
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Revised model
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 217
Study: 32798785

Group type: EXPERIMENTAL
Intervention: Diffusion spectrum imaging−based fiber tracking
Number of subjects: 10
Study: 34889352

Group type: EXPERIMENTAL
Intervention: Ticket to Home (TTH) survey tool before discharge
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care (without TTH survey tool)
Number of subjects: 100
Study: 34551215

Group type: EXPERIMENTAL
Intervention: iGlarLixi + insulin glulisine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Multiple daily injection therapy
Number of subjects: 40
Study: 33788975

Group type: EXPERIMENTAL
Intervention: Active aiTBS
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sham (Control)
Number of subjects: 50
Study: 35804406

Group type: EXPERIMENTAL
Intervention: Evidence-based traditional Chinese medicine massage (2 sessions per week for 10 weeks)
Number of subjects: 300

Group type: COMPARATOR
Intervention: External Diclofenac Diethylamine Emulgel (3-4 times per day for 10 weeks)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Evidence-based traditional Chinese medicine massage
Number of subjects: 300

Group type: COMPARATOR
Intervention: External Diclofenac Diethylamine Emulgel
Number of subjects: 300
Study: 33540680

Group type: EXPERIMENTAL
Intervention: Femtosecond laser-assisted cataract surgery (FLACS)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Conventional cataract surgery
Number of subjects: 130
Study: 32403999

Group type: EXPERIMENTAL
Intervention: Percutaneous neuromodulation (PNM)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Needle technique (without electrical stimulation)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Neurodynamic sciatic sliding technique
Number of subjects: 80

Group type: COMPARATOR
Intervention: Hamstring stretching
Number of subjects: 80
Study: 32697618

Group type: EXPERIMENTAL
Intervention: Methyldopa
Number of subjects: 486

Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 486

Group type: COMPARATOR
Intervention: Control (no medication)
Number of subjects: 486
Study: 33832116

Group type: EXPERIMENTAL
Intervention: Chaihu Guizhi decoction (CGD), administered twice a day for 7 days after TACE.
Number of subjects: 0

Group type: COMPARATOR
Intervention: CGD simulations (placebo), administered twice a day for 7 days after TACE.
Number of subjects: 0
Study: 32164440

Group type: EXPERIMENTAL
Intervention: Novel community-based enhanced care intervention
Number of subjects: 60
Study: 35486445

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet (LCD)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Weight change
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Change in zonulin
Number of subjects: 45
Study: 34619438

Group type: EXPERIMENTAL
Intervention: ND0612 (levodopa/carbidopa) infusion
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo infusion + standard of care (SoC)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: ND0612 plus oral entacapone
Number of subjects: 16

Group type: COMPARATOR
Intervention: Standard of care (SoC) levodopa/carbidopa
Number of subjects: 16
Study: 35550468

Group type: EXPERIMENTAL
Intervention: Sinomenine (zhengqing fengtongning sustained-release tablets) administered for 12 weeks along with febuxostat (40 mg/d) and anti-inflammatory prophylaxis therapy.
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Sinomenine (zhengqing fengtongning sustained-release tablets) administered for 12 weeks.
Number of subjects: 210

Group type: COMPARATOR
Intervention: Colchicine placebo administered for 12 weeks along with febuxostat (40 mg/d) and anti-inflammatory prophylaxis therapy.
Number of subjects: 210

Group type: COMPARATOR
Intervention: Colchicine administered for 12 weeks.
Number of subjects: 210
Study: 32966919

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (300 IU/kg up to a maximum of 6000 IU daily)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 34838475

Group type: EXPERIMENTAL
Intervention: EWS + MTM
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: EWS
Number of subjects: 188

Group type: COMPARATOR
Intervention: SS (control)
Number of subjects: 188
Study: 33989455

Group type: EXPERIMENTAL
Intervention: Higher levels of personality disorder traits
Number of subjects: 69

Group type: COMPARATOR
Intervention: Lower levels of personality disorder traits
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Patients with PD
Number of subjects: 69

Group type: COMPARATOR
Intervention: Patients without PD
Number of subjects: 69
Study: 32945536

Group type: EXPERIMENTAL
Intervention: Intravenous alcohol administration
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo (water cues)
Number of subjects: 27
Study: 35263457

Group type: EXPERIMENTAL
Intervention: Fertile Chip
Number of subjects: 128

Group type: COMPARATOR
Intervention: Traditional swim-up procedures
Number of subjects: 128
Study: 32807873

Group type: EXPERIMENTAL
Intervention: Ultraviolet-filtering IOL (UVF-IOL)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Blue-light-filtering IOL (BF-IOL)
Number of subjects: 7
Study: 33096333

Group type: EXPERIMENTAL
Intervention: Tailored internet-based intervention (IMI) program
Number of subjects: 360

Group type: COMPARATOR
Intervention: Enhanced treatment as usual
Number of subjects: 360
Study: 32001798

Group type: EXPERIMENTAL
Intervention: Daratumumab plus lenalidomide/dexamethasone (D-Rd)
Number of subjects: 569